您当前的位置:
HET0016
目录号: PC12786 纯度: ≥98%
CAS No. :339068-25-6
商品编号 规格 价格 会员价 是否有货 数量
PC12786-5mg 5mg ¥987.84 请登录
PC12786-10mg 10mg ¥1742.44 请登录
PC12786-100mg 100mg ¥13034.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
HET0016
中文别名
N-羟基-n-(4-丁基-2-甲基苯基)甲脒
英文名称
HET0016
英文别名
N-Hydroxy-N’-(4-butyl-2-methylphenyl)formamidine;HET0016;HET-0016;Methanimidamide, N-(4-butyl-2-methylphenyl)-N'-hydroxy-;N'-(4-butyl-2-methylphenyl)-N-hydroxymethanimidamide;N-Hydroxy-N'-(4-butyl-2-Methylphenyl)forMaMidine;HMS1445D06
Cas No.
339068-25-6
分子式
C12H18N2O
分子量
206.28
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
生物活性

HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth.

性状

Solid

IC50 & Target[1][2]

CYP4

 

体外研究(In Vitro)

HET0016 is a selective, non-competitive and irreversible inhibitor of CYP4A .
HET0016 (100 μM; 24 hours, 48 hours) decreases migration and invasion of breast cancer metastatic cells .

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line: MDA-MB-231 cells
Concentration: 100 μM
Incubation Time: 24 hours, 48 hours
Result: Decreased migration and invasion of breast cancer metastatic cells
体内研究(In Vivo)

HET0016 (10 mg/kg/day; i.v.; for 3 weeks) reduces tumor volume and lung metastasis in an immunocompetent breast cancer mouse model.
HET0016 reduces the metalloproteinases’ levels in the lungs via PI3K/AKT pathway in mice.
HET0016 decreases expression of pro-inflammatory and growth factors and granulocytic MDSCs population in lung microenvironment.
HET0016 protects BBB dysfunction after I/R by regulating the expression of MMP-9 and tight junction proteins.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 4–5 weeks female Balb/c mice (16-18 g)
Dosage: 10 mg/kg/day
Administration: Intravenously; 5 days a week; for 3 weeks; starting from day 15 of tumor implantation
Result: Reduced tumor volume and lung metastasis.
运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献
溶解度数据
体外研究: 

DCM : 12.5 mg/mL (60.60 mM; Need ultrasonic)

DMSO : 5 mg/mL (24.24 mM; Need ultrasonic)

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.8478 mL 24.2389 mL 48.4778 mL
5 mM 0.9696 mL 4.8478 mL 9.6956 mL
10 mM 0.4848 mL 2.4239 mL 4.8478 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 20% HP-β-CD in saline

    Solubility: 2 mg/mL (9.70 mM); Clear solution; Need ultrasonic

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2